Filing search / Legend Biotech Corporation / "Retention"

6-K

EX-99.1

LEGN Legend Biotech Corporation

20 Sep 24

Current report (foreign)

8:01am

and consultants and to take advantage of the significant motivation and retention benefits provided by equity compensation. Our Board, based on recommendation

F-3ASR

LEGN Legend Biotech Corporation

19 Mar 24

Automatic shelf registration (foreign)

7:57am

and retention of such third party providers and local agents, they will not be responsible for any errors or omissions made by them in providing the relevant

F-3ASR

r47y rhfy7v

26 May 23

Automatic shelf registration (foreign)

9:01am

424B5

95chfkp g7

8 May 23

Prospectus supplement for primary offering

8:45am

6-K

EX-99.1

o8jxci2

14 Apr 23

Master Technology Transfer, Manufacturing and Clinical Supply Services Agreement for Bcma Car-t Product

8:30am

6-K

EX-1.1

h6updv07

27 Jul 22

Announces Pricing of Public Offering

4:35pm

424B5

0nrr34 2sugsqd

27 Jul 22

Prospectus supplement for primary offering

4:32pm

424B5

82osv2jj rlya

25 Jul 22

Prospectus supplement for primary offering

4:29pm

6-K

EX-1.1

6w0saskwp

17 Dec 21

Announces Pricing of Public Offering

4:19pm

424B5

p8lsnlqr

17 Dec 21

Prospectus supplement for primary offering

4:16pm

424B5

su8c z7gd

14 Dec 21

Prospectus supplement for primary offering

4:40pm

424B3

w3owvc

14 Jul 21

Prospectus supplement

4:06pm

F-3

7034pm26l1v

2 Jul 21

Shelf registration (foreign)

7:36am